378 related articles for article (PubMed ID: 28840016)
21. EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotype.
Warth A; Penzel R; Lindenmaier H; Brandt R; Stenzinger A; Herpel E; Goeppert B; Thomas M; Herth FJ; Dienemann H; Schnabel PA; Schirmacher P; Hoffmann H; Muley T; Weichert W
Eur Respir J; 2014 Mar; 43(3):872-83. PubMed ID: 23988776
[TBL] [Abstract][Full Text] [Related]
22. Programmed death-ligand 1 expression and its associations with clinicopathological features, prognosis, and driver oncogene alterations in surgically resected lung adenocarcinoma.
Takamochi K; Hara K; Hayashi T; Kohsaka S; Takahashi F; Suehara Y; Suzuki K
Lung Cancer; 2021 Nov; 161():163-170. PubMed ID: 34600407
[TBL] [Abstract][Full Text] [Related]
23. Genomic Landscape and Immune Microenvironment Features of Preinvasive and Early Invasive Lung Adenocarcinoma.
Zhang C; Zhang J; Xu FP; Wang YG; Xie Z; Su J; Dong S; Nie Q; Shao Y; Zhou Q; Yang JJ; Yang XN; Zhang XC; Li Z; Wu YL; Zhong WZ
J Thorac Oncol; 2019 Nov; 14(11):1912-1923. PubMed ID: 31446140
[TBL] [Abstract][Full Text] [Related]
24. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
[TBL] [Abstract][Full Text] [Related]
25. Genotyping and cytomorphological subtyping of lung adenocarcinoma based on liquid-based cytology.
Tanaka R; Sakamoto N; Suzuki H; Tachibana K; Ohtsuka K; Kishimoto K; Fujiwara M; Kamma H; Shibahara J; Kondo H
Diagn Cytopathol; 2019 Jun; 47(6):564-570. PubMed ID: 30741488
[TBL] [Abstract][Full Text] [Related]
26. Breaking the Invisible Barriers: Unleashing the Full Potential of Immune Checkpoint Inhibitors in Oncogene-Driven Lung Adenocarcinoma.
Kwok HH; Yang J; Lam DC
Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345086
[TBL] [Abstract][Full Text] [Related]
27. Assessment of DDR2, BRAF, EGFR and KRAS mutations as therapeutic targets in non-adenocarcinoma lung cancer patients.
Yashima H; Shimizu K; Araki T; Aomori T; Ohtaki Y; Nagashima T; Enokida Y; Atsumi J; Nakamura T; Takeyoshi I; Yamamoto K
Mol Clin Oncol; 2014 Sep; 2(5):714-718. PubMed ID: 25054035
[TBL] [Abstract][Full Text] [Related]
28. Association of histologic subtypes with genetic alteration and PD-L1 expression in pulmonary adenocarcinoma.
Phruttinarakorn B; Reungwetwattana T; Incharoen P
Mol Clin Oncol; 2020 Sep; 13(3):12. PubMed ID: 32754326
[TBL] [Abstract][Full Text] [Related]
29. Pathologic complete response to preoperative immunotherapy in a lung adenocarcinoma patient with bone metastasis: A case report.
Tang Y; Li Y; Zhang L; Tong G; Ou Z; Wang Z; Zhang H; Qiao G
Thorac Cancer; 2020 Apr; 11(4):1094-1098. PubMed ID: 32077636
[TBL] [Abstract][Full Text] [Related]
30. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma.
Cai G; Wong R; Chhieng D; Levy GH; Gettinger SN; Herbst RS; Puchalski JT; Homer RJ; Hui P
Cancer Cytopathol; 2013 Sep; 121(9):500-7. PubMed ID: 23495083
[TBL] [Abstract][Full Text] [Related]
31. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.
Wen S; Dai L; Wang L; Wang W; Wu D; Wang K; He Z; Wang A; Chen H; Zhang P; Dong X; Dong YA; Wang K; Yao M; Wang M
Oncologist; 2019 Nov; 24(11):e1070-e1081. PubMed ID: 30902917
[TBL] [Abstract][Full Text] [Related]
32. Integration of clinicopathological and mutational data offers insight into lung cancer with tumor spread through air spaces.
Tian Y; Feng J; Jiang L; Ning J; Gu Z; Huang J; Luo Q
Ann Transl Med; 2021 Jun; 9(12):985. PubMed ID: 34277785
[TBL] [Abstract][Full Text] [Related]
33. Somatic mutations and immune checkpoint biomarkers.
Parris BA; Shaw E; Pang B; Soong R; Fong K; Soo RA
Respirology; 2019 Mar; 24(3):215-226. PubMed ID: 30636374
[TBL] [Abstract][Full Text] [Related]
34. Programmed cell death ligand 1 expression in cytologic and surgical non-small cell lung carcinoma specimens from a single institution: Association with clinicopathologic features and molecular alterations.
Mei P; Shilo K; Wei L; Shen R; Tonkovich D; Li Z
Cancer Cytopathol; 2019 Jul; 127(7):447-457. PubMed ID: 31025831
[TBL] [Abstract][Full Text] [Related]
35. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596
[TBL] [Abstract][Full Text] [Related]
36. Expression Changes in Programmed Death Ligand 1 from Precancerous Lesions to Invasive Adenocarcinoma in Subcentimeter Pulmonary Nodules: A Large Study of 2022 Cases in China.
Yang X; Xiao Y; Hu H; Qiu ZB; Qi YF; Wang MM; Wu YL; Zhong WZ
Ann Surg Oncol; 2023 Nov; 30(12):7400-7411. PubMed ID: 37658270
[TBL] [Abstract][Full Text] [Related]
37. Driver gene alterations profiling of Chinese non-small cell lung cancer and the effects of co-occurring alterations on immunotherapy.
Sun S; Du W; Sun Q; Zhao X; Qin B; Shi D; Wan C; Wu Z
Cancer Med; 2021 Oct; 10(20):7360-7372. PubMed ID: 34599863
[TBL] [Abstract][Full Text] [Related]
38. Molecular profiling of advanced non-small cell lung cancer in the era of immunotherapy approach: a multicenter Italian observational prospective study of biomarker screening in daily clinical practice.
Vavala T; Malapelle U; Veggiani C; Ludovini V; Papotti M; Leone A; Graziano P; Minari R; Bono F; Sapino A; Manotti L; Troncone G; Pisapia P; Girlando S; Buffoni L; Righi L; Colantonio I; Bertetto O; Novello S
J Clin Pathol; 2022 Apr; 75(4):234-240. PubMed ID: 33509945
[TBL] [Abstract][Full Text] [Related]
39. The expression of
Jia X; Qian R; Zhang B; Zhao S
J Thorac Dis; 2016 Oct; 8(10):2682-2688. PubMed ID: 27867542
[TBL] [Abstract][Full Text] [Related]
40. Case Report: Chemotherapy-free treatment with camrelizumab and anlotinib for elderly patients with
Qi W; Xi D; Bai Y; Liu L; Ma Y; Yin Z; Chen H
Front Pharmacol; 2023; 14():1026135. PubMed ID: 36713848
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
